Clinical trial · Interventional
Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer
NCT06742021CI-TRIAL-00083931recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to address the challenge of predicting the efficacy of targeted and immunotherapy in lung cancer patients. By utilizing two DCE-MRI images-one before treatment and one after one treatment cycle-along with the patients' clinical and pathological information, we aim to achieve accurate prediction of the therapeutic efficacy of targeted and immunotherapy in lung cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer
- description
- A Philips 3.0T MRI scanner was used, with a dStream Torso 32-channel coil. DCE-MRI was performed using a free-breathing sequence with a flow velocity of 3.0 m/s. The image quality assessment in this study was performed by two radiologists (one with 3 years of diagnostic experience and the other with 15 years of diagnostic experience), including both subjective and objective evaluations. Then, dynamic information from the 4D FreeBreathing DCE-MRI images taken before treatment and one week after immunotherapy/targeted therapy, along with routine clinical and pathological data, were used to construct predictive models for the efficacy of immunotherapy and targeted therapy. Finally, the MRI model was compared with the CT model, and the performance of both models was evaluated.
- interventionNames
- Diagnostic Test: Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer
Primary outcomes (1)
- measure
- Tumor treatment response evaluation
- timeFrame
- within one week before treatment and two weeks after treatment completion
- description
- This study aims to evaluate tumor treatment response using the RECIST V1.1 criteria, based on CT images taken within one week before treatment and two weeks after treatment completion.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Tumor size greater than 2 cm 2. Age between 18 and 75 years Exclusion Criteria: 1. Presence of MRI contraindications (e.g., metal implants, pacemaker implantation, etc.) 2. Allergy to gadolinium contrast agents 3. Lesions difficult to delineate on images due to conditions such as atelectasis or diffuse lesions
References
Publications (0)
Data not yet available
No reference posted for this study.